Organisation paid for research Program year 2025 Source: CMS Open Payments

Hope Neurology, PLLC

Neither a doctor nor a teaching hospital

Research payments

$306,233

13 payments

Through program year 2025, Hope Neurology, PLLC is reported as receiving $306,233 in research payments, across 13 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$46,352	5
2024	Research	$32,271	1
2023	Research	$57,262	2
2022	Research	$42,138	2
2021	Research	$45,566	1
2020	Research	$82,644	2

Breakdown

Who paid Research payments · program years 2020–2025

Celgene Corporation $300,827 11 payments
E.R. Squibb & Sons, L.L.C. $5,406 2 payments

Studies the money was for Research payments · program years 2020–2025

A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) $98,539 3 payments
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) (BMS Study Number: IM047-P46) $51,836 1 payment
A Multicenter, Longitudinal, Open-Label, Single-Ar $45,566 1 payment
PhIII Efficacy And Safety of RPC1063 in Relapsing MS (RPC01-3001) $30,808 1 payment
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. $29,691 2 payments
A Phase 2 Study of RPC01-1063 in Patients with Multiple Sclerosis $24,740 2 payments
A Multicenter, Longitudinal, Open-Label, Single-Ar - A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) $19,900 1 payment
A Phase 3B, Multicenter, Open-Label Study to Evaluate the Immunological Response To, and the Safety Of, Three Parenterally Administered Vaccines in Subjects With Relapsing Remitting Multiple Sclerosis Who Receive Oral Ozanimod, Non-Pegylated Interferon-, Or No Disease Modifying Therapy $3,500 1 payment
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. $1,653 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.